Could a common vitamin help fix low blood counts?

NCT ID NCT07579429

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether two dietary supplements—nicotinamide riboside (a vitamin B3 derivative) and pterostilbene (a plant compound)—can safely improve low blood counts in people with lower-risk myelodysplastic syndrome (MDS) or high-risk clonal cytopenia of undetermined significance (CCUS). Ten participants will receive different doses to see if hemoglobin levels rise by at least 1 g/dL over 24 weeks. The study is open-label and aims to check both effectiveness and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nicotinamide riboside and pterostilbene (dietary supplements)
What this could lead to: If it works, this could point toward a simple supplement-based way to improve low blood counts in people with certain blood disorders.
What could go wrong: This is a very small early-phase trial with only 10 participants, so results may not apply widely. Supplements may not improve blood counts or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

University of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.